Top Markets
#1 Pleasing Gold Pleasing Gold +1,501.12%
#2 PulseChain PulseChain +54.75%
#3 Ontology Gas Ontology Gas +36.56%
#4 Merlin's Seal BTC Merlin's Seal BTC +33.29%
#5 BOOK OF MEME BOOK OF MEME +30.64%
#6 ConstitutionDAO ConstitutionDAO +26.74%
#7 Unit Pump Unit Pump +26.20%
#8 Pump.fun Pump.fun +24.87%
#9 Neiro Neiro +24.52%
#10 Collect on Fanable Collect on Fanable +24.26%
Coin of the day
Pleasing Gold Pleasing Gold
設定
言語
日本
通貨
USD
テーマ
Molecure S.A. Molecure S.A.

Molecure S.A.

MOC
株式のランク #26168
Operating as a biopharmaceutical firm in Poland, Molecure S.A. specializes in... Operating as a biopharmaceutical firm in Poland, Molecure S.A. specializes in the research, development, and commercialization of innovative therapies designed to combat neoplastic (cancer) and inflammatory conditions. The company's pipeline prominently features OATD-01, a chitotriosidase/acidic mammalian chitinase inhibitor that has successfully advanced through Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis and sarcoidosis. Additionally, Molecure is progressing its YKL-40 program for cancer and fibrosis, OATD-02 for oncology applications, and a Deubiquitinase program. Established in 2012, this Warsaw-headquartered enterprise adopted the name Molecure S.A. in March 2022, having previously been known as OncoArendi Therapeutics S.A.
株価
$1.73
時価総額
$42.88M
変化（1日）
2.16%
変化（1年）
-18.85%
国
PL
取引 Molecure S.A. (MOC)

カテゴリー

Healthcare
Molecure S.A.（MOC）の収益
Aug 2026 時点の収益 TTM: 0
Molecure S.A. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Molecure S.A. の収益履歴（2026 ～ 2026）
各年末の収益
年 収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US